Topotecan fluorescence

Maprotiline
Bidil
Docetaxel
Symmetrel

Topotecan TPT ; , a known inhibitor of topoisomerase I, has previously been shown to inhibit the replication of several viruses. The mechanism of inhibition was proposed to be the inhibition of topoisomerase I. We report that TPT decreased replication of human immunodeficiency virus type 1 HIV-1 ; in CPT-K5, a cell line with a topoisomerase I mutation. TPT inhibited production of HIV-1 RNA and p24 in CPT-K5 and wild-type cells equally effectively. The antiviral effects of TPT were observed not only in the topoisomerase-mutated CPT-K5 line but also in peripheral blood mononuclear cells PBMC ; acutely infected with clinical isolates and in OM10.1 cells latently infected with HIV and activated by tumor necrosis factor alpha. Little toxicity from TPT was noted in HIV-1-infected PBMC and in CPT-K5 and OM10.1 cells as measured by cell growth and proliferation assays. These observations suggest that TPT targets factors in virus replication other than cellular topoisomerase I and inhibits cytokine-mediated activation in latently infected cells by means other than cytotoxicity. These results suggest a potential for TPT and for other camptothecins in anti-HIV therapy alone and in combination with other antiretroviral drugs. Topotecan TPT ; , a semisynthetic analog of camptothecin CPT ; , is a potent topoisomerase I topo I ; inhibitor. As an antineoplastic agent, TPT has a more favorable side-effect profile than CPT and has been approved for the treatment of ovarian cancer 8, 18, 22, ; . CPT and its analogs produce drug-induced accumulation of topo I-DNA complexes in vitro and in vivo 5, 7, 912 ; . These complexes inhibit topo I activity and lead to single-strand breaks in DNA. As a result, these drugs inhibit DNA replication and terminate RNA transcription at sites of complex formation 3, 13, 14 ; . The antiviral activity of CPT and its analogs has been reported in several studies. These antiviral activities have been related to cellular topo I, virus-associated topo I, human immunodeficiency virus HIV ; reverse transcriptase RT ; , or the HIV long terminal repeat LTR ; 17, 20, 21, ; . We have shown that TPT selectively inhibits HIV type 1 HIV-1 ; LTR-directed lacZ gene expression in a human epithelial cell line 17 ; and also found that TPT inhibits both acute and chronic HIV-1 infections. The question of whether TPT's antiHIV activity is related to inhibition of topo I remained. In this report we show that the anti-HIV effect of TPT may be independent of its anti-topo I activity. We examined the anti-HIV activity of TPT in CPT-K5, a chronically infected cell line carrying a topo I mutation 2, 26 ; . The anti-HIV activity of TPT was also examined in a latently infected cell line activated by tumor necrosis factor alpha TNF- ; and in peripheral blood mononuclear cells PBMC ; acutely infected with clinical isolates. This work was presented in part at the 3rd National Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 1996. 13 Evan Feigenbaum, "The Military Transforms China: The Politics of Strategic Technology from the Nuclear to the Information Age, " 1997, p. 347. 14 Evan Feigenbaum, "The Military Transforms China: The Politics of Strategic Technology from the Nuclear to the Information Age, " 1997, p. 372. 12.

Topotecan patient assistance

Toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 2. No dose interruption or modification was made for grade 1 non-hematologic toxicity. Doses were reduced for hematologic and other toxicities. In the event of a grade 3 or 4 hematologic toxicity, only topotecan was reduced. In the event of a grade 4 non-hematologic toxicity, both topotecan and UCN-01 were reduced. Dose adjustments were made according to the system showing the greatest degree of toxicity. Doses that were reduced for toxicity were not re-escalated. The treatment of a patient could be postponed for up to 2 weeks if he she had not recovered from hematologic and or non-hematologic toxicity at the beginning of a cycle day 1 ; . Treatment was restarted immediately after recovery; that is, neutrophils 1.5 109 l, platelets 100 109 l, and recovery from non-hematologic toxicities. A patient was discontinued from the study if the beginning of a given cycle was postponed due to toxicity for more than 2 weeks, unless approved by the CTEP drug monitor.
Rheumatoid Involvement of the Hand and Wrist Ribs, Resection of, in Thoracoplasty . Richards Manufacturing Company Fellowships Rickets, Renal, Slipped Capital Femoral Epiphysis in.

No dosage adjustment is required in patients with hepatic impairment serum bilirubin in the range 25.65 to 171 mol L ; . Hepatically impaired patients were able to tolerate 1.5mg m2 for five days every three weeks although a small reduction in topotecan clearance was observed.
1. Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecanpaclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001; 19: 18931900. Rose PG, Gordon NH, Fusco N et al. A phase II and pharmacokinetic study of weekly 72 h topotecan infusion in patients with platinumresistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000; 78: 228234. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 21832193. Armstrong D, Rowinsky E, Donehower R et al. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Assoc Cancer Res 1995; 14: 275 Abstr A769 ; . 5. von Hoff DD, Burris HA, Eckardt J et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34: 4145. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 30563061. Tolis C, Peters GJ, Ferreira CG et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35: 796807. Sun W, Stevenson JP, Giantonio B et al. A phase I trial of topotecan and gemcitabine administered weekly for consecutive weeks to patients with advanced tumours. Cancer 2001; 15: 414419. Sehouli J, Lichtenegger W, Schnborn J et al. Phase I trial of topotecan in combination with gemcitabine in platinum and paclitaxel refractory ovarian cancer. Proc Soc Clin Oncol 1999; 18: Abstr 1482 ; . 10. Ganem G, Gladieff L, Guastalla JP et al. Sequential topotecan and etoposid in pre-treated ovarian cancer: a GINECO phase II study. Proc Soc Clin Oncol 1998; 18: Abstr 1371 ; . 11. Perry MC. National Cancer Institute Common Toxicity Criteria: the chemotherapy source book. Baltimore, MD: Williams & Wilkins 1990; 11331140 and toradol.

Topotecan and avastin for ovarian cancer

Table 1 Analysis of plasma topotecan after injection of free or liposomal drug Plasma concentration g ml ; Time Free topotecan 5 min 15 min Liposomal topotecan 30 min 1h 4h 16 Lactone 1.5 1.4 56.5 Carboxylate 1.6 1.0 2.0 Total 3.1 2.4 58.5 Topotecan % of total ; Lactone 48 58 97 Carboxylate 52 42 3. Urohypophysis'te Blm Ed.: H. Heller ve B.T. Pickering ; , International Encylopedia of Pharmacology and Therapeutics, 1. Cilt, s. 399, Pergamon, Oxford, 1970. Tommwambingu, H.: Water intoxication and oxytocin. Brit. Med. J. 290: 13, 1985. Tromans, P.M. ve di.: Comparative study of estradiol and prostaglandin E2 vaginal gel for ripening the unfavourable cervix before induction of labour. Brit. Med. J. 282: 679, 1981. X. BLM: OTAKO DLER 86. Histamin ve Antihistaminikler Ahmad, S.R.: Antihistamines alert. Lancet 340: 542, 1992. Arrang, J.M. ve di.: Highly potent and selective ligands for histamine H3 receptors. Nature 327: 117, 1987. Asthon, M.G. ve di.: Healing of gastric ulcers after one, two and three months of ranitidine. Brit Med. J. 284: 467, 1982. Avella, J. ve di.: Effect of histamine H2 receptor antagonist on delayed hypersensitivity. Lancet 1: 624, 1978. Awcuters, F.H.L. ve di.: Pharmacology of the specific histamine H1 antagonist astemizole. Arzneim.Forsch. 33. 381, 1983. Axelrod, J. ve F. Hirata: Phospholipid methylation and receptor induced release of histamine from cells. TIPS 3: 156, 1982. Bardhan, K.D. ve di.: Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate. Brit. Med. J. 284: 621, 1982. Bays, D.E. ve R. Sables: Recent developments in the use of H2 antagonist to treat peptic ulcers. Pharmacy Int. 4: 199, 1983 Beaven, M.A.: Histamine. N. Engl. J. Med. 294: 30 ve 320, 1976. Block, J.W. ve di.: Definition and antagonism of histamine H2 receptors. Nature 236: 385, 1972. Brogden, R.N. ve di.: Cimetidine a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 15: 93, 1978. Cargill, J.M. ve di.: Very longterm treatment of peptic ulcer with cimetidine. Lancet 2: 1113, 1978. Chand, N. Distribution and classification of airway histamine receptors: The physiological significance of histamine H2 receptors: Adv. Pharmacol. Chemother. 17: 103, 1980. Cheng, H.C. ve J.K. Woodward: Antihistamine effect of terfenadine. Drug. Dev. Res 2: 181, 1982. Clain, J.E.: Diagnosis and management of gastrinoma ZollingerEllison syndrome ; . Mayo Clin. Proc. 57: 265, 1982. Cohen, A.F. ve di.: The acute effects of acrivastine BW 825 C ; , a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects. Clin. Pharmacol Ther. 38. 381, 1985. Czerwonka, R. ve di.: Release of histamine by H2 receptor antagonists. Lancet 2: 216, 1987. Danilewitz, M. ve di.: Ranitidine supression of gastric hypersecretion resistant to cimetidine. N. Engl. J. Med. 306: 20, 1982. DeFeudis, F.V.: Studies on endotheliumdependent vasorelaxation. Gen. Pharmacol 17: 1, 1986. Dale, M.M. ve J.C. Foreman: Textbook of Immunopharmacology, 2nd Ed., Blackwell, Oxford, 1989. Dial, E. ve di.: Isolated parietal cells: histamine response and pharmacology. JPET 219: 585, 1981. Donoso, A.O. ve M. Barontini: Increase in plasma catecholami and toremifene.

Topotecan msds

There is some evidence that befriending given to women with chronic depression as an adjunct to drug or psychological treatment may increase the likelihood of remission. Relapsed ovarian cancer and small cell lung cancer are frequently treated with topotecan Hycamtin ; , for which the standard dose and schedule are 1.5 mg m2 daily for five consecutive days every 3 weeks. Clinical experience has shown that this dose and schedule may be too toxic for some patients, especially those who have been heavily pretreated with platinum-based therapeutics, and it has been suggested that starting doses of topotecan be reduced to 1.01.25 mg m2 d. Recently, multiple clinical trials have begun to evaluate the feasibility and preliminary antitumor activity of an alternative schedule based on weekly administration of topotecan. The potential benefits of weekly administration include not only reduced toxicity without significant compromise of antitumor activity, but also greater patient convenience and quality of life and greater potential for developing new topotecan-containing combination therapies. This report reviews the rationale for a weekly schedule, as well as a growing base of emerging clinical data. These preliminary data suggest that weekly topotecan is active; further evaluations are planned to confirm the activity and therapeutic index and to determine optimal dosing of a weekly schedule. The Oncologist 2002; 7: 324-330 and torsemide.

This pilot study provides the first evidence of a significant improvement of vasomotor reactivity by statin therapy in patients with cerebral small-vessel disease. The effect was more pronounced in patients with a more severe impairment of vasomotor reactivity. Because the baseline CBFVmean remained unchanged, the findings indicate a specific effect of pravastatin on the reactivity of the cerebral microvasculature. Despite a considerable interindividual variability in CBFVmean and vasomotor reactivity, this effect was present even when absolute increases before and after pravastatin treatment were compared. Pretreatment vasomotor reactivity and the effect of pravastatin were independent of baseline CBFVmean, excluding that the results were confounded by different levels of baseline values. It should be mentioned that pravastatin considerably enhanced vasomotor reactivity even though we applied a relatively low dosage 20 mg daily ; as compared with previous studies.1 From a pathophysiological point of view, it is tempting to speculate that the observed increase in vasomotor reactivity was the result of an improvement of endothelial function. Statin treatment has been shown to improve NO-dependent coronary vasomotor regulation and endothelial function in the forearm vasculature in patients with Ideally, the cost effectiveness of treatments should be expressed in terms of incremental cost per quality adjusted life year If the evidence allows, the use of these drugs in the subgroup of women with relapsed ovarian cancer that is potentially platinum sensitive that is, relapse or progression occurring 6 months or more after completing previous platinum-based therapy ; will be considered. If relevant, and if the evidence allows, administration in different settings for example in the home ; will be considered. Current NICE guidance No. 3 - Guidance on the use of taxanes for ovarian cancer. Issued May 2000 superseded by No. 55 ; No. 28 - Guidance on the use of topotecan for the treatment of advanced ovarian cancer. Issued August 2001 No. 45 - Guidance on the use of pegylated liposomal doxorubicin hydrochloride PLDH ; for the treatment of advanced ovarian cancer. Issued July 2002 No. 55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer. Issued January 2003 and tracleer.

Discount generic Topotecan online

The Cu + and Au + aqua ion is known to be unstable in aqueous solution, especially under alkaline conditions. However, gold I ; solutions in mixtures of acetonitrile and dilute mineral acids have been used to determined a first hydrolysis constant of Au + [3]. Similar deviation from the expected hydrolysis strength was also observed for the Ra2 + cation [5] of the Group 2 and the Rf4 + cation of the Group 4 [6]. Am J Physiol Regulatory Integrative Comp Physiol 276: 559-565, 1999. You might find this additional information useful. This article cites 20 articles, 8 of which you can access free at: : ajpregu.physiology cgi content full 276 2 R559#BIBL This article has been cited by 1 other HighWire hosted article: Lengthening contraction-induced inflammation is linked to secondary damage but devoid of neutrophil invasion B. M. Lapointe, J. Frenette and C. H. Cote J Appl Physiol, May 1, 2002; 92 ; : 1995-2004. [Abstract] [Full Text] [PDF] Medline items on this article's topics can be found at : highwire anford lists artbytopic.dtl on the following topics: Medicine . Fatigue Physiology . Rats and trandolapril.

Levels ; within peripheral blood lymphocytes to those of the tumor is potentially inappropriate. The sequential administration of doxorubicin and topotecan produces acceptable clinical toxicity myelosuppression ; and evidence of antitumor activity, especially in small cell lung cancer. There is no evidence to suggest that doxorubicin altered the pharmacokinetics of topotecan. In addition, there was no apparent relationship between the Cmax or AUC of topotecan and toxicity or response to therapy. The measure of topoisomerase-I, -II , and -II mRNA levels in PBMCs showed a frequent and substantial effect of these agents, although no consistent pattern was observed for either topoisomerase I and topoisomerase II . Topoisomerase II mRNA levels showed a more consistent pattern and a suggestion of differing patterns in responding and nonresponding patients. The clinical utility of sequencing doxorubicin and topotecan is currently under investigation in a Phase II trial in non-Hodgkin's Lymphoma in a national cooperative group trial. 23. Lamba, J. K., M. Adachi, D. Sun, J. Tammur, E. G. Schuetz, R. Allikmets, and J. D. Schuetz. 2003. Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum. Mol. Genet. 12: 99109. 24. Meijer, D. K., G. J. Hooiveld, A. H. Schinkel, J. E. van Montfoort, M. Haas, D. de Zeeuw, F. Moolenaar, J. W. Smit, and P. J. Meier. 1999. Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol. Dial. Transplant. 14 Suppl. 4 ; : 13. 25. Miller, D. S., S. N. Nobmann, H. Gutmann, M. Toeroek, J. Drewe, and G. Fricker. 2000. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58: 13571367. 26. Mottino, A. D., T. Hoffman, L. Jennes, and M. Vore. 2000. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. 293: 717723. 27. Naesens, L., J. Balzarini, and E. De Clercq. 1992. Pharmacokinetics in mice of the anti-retrovirus agent 9- 2-phosphonylmethoxyethyl ; adenine. Drug Metab. Dispos. 20: 747752. 28. Pandey, H. P., A. Ram, H. Matsumura, S. Satoh, and O. Hayaishi. 1995. Circadian variations of prostaglandins D2, E2, and F2 alpha in the cerebrospinal fluid of anesthetized rats. Biochem. Biophys. Res. Commun. 213: 625 629. Paulusma, C. C., M. J. Kothe, C. T. Bakker, P. J. Bosma, B. van, I., J. van Marle, U. Bolder, G. N. Tytgat, and R. P. Oude Elferink. 2000. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31: 684693. 30. Rao, V. V., J. L. Dahlheimer, M. E. Bardgett, A. Z. Snyder, R. A. Finch, A. C. Sartorelli, and D. Piwnica-Worms. 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA 96: 39003905. 31. Reid, G., P. Wielinga, N. Zelcer, I. van der Heijden, A. Kuil, M. de Haas, J. Wijnholds, and P. Borst. 2003. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA 100: 9244 9249. Rubin, L. L., and J. M. Staddon. 1999. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22: 1128. 33. Samad, T. A., K. A. Moore, A. Sapirstein, S. Billet, A. Allchorne, S. Poole, J. V. Bonventre, and C. J. Woolf. 2001. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471475. 34. Sampath, J., M. Adachi, S. Hatse, L. Naesens, J. Balzarini, R. M. Flatley, L. H. Matherly, and J. D. Schuetz. 2002. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm. Sci. 4: E14. 35. Scheffer, G. L., M. Kool, M. Heijn, M. De Haas, A. C. Pijnenborg, J. Wijnholds, A. van Helvoort, M. C. de Jong, J. H. Hooijberg, C. A. Mol, L. M. van der, J. M. de Vree, d. van, V., R. P. Elferink, P. Borst, and R. J. Scheper. 2000. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 60: 52695277. 36. Schinkel, A. H., J. J. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. Van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, and H. P. te Riele. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491502. 37. Schuetz, J. D., M. C. Connelly, D. Sun, S. G. Paibir, P. M. Flynn, R. V. Srinivas, A. Kumar, and A. Fridland. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5: 1048 1051. Spector, R. 1976. Inhibition of methotrexate transport from cerebrospinal fluid by probenecid. Cancer Treat. Rep. 60: 913916. 39. Stewart, C. F., S. D. Baker, R. L. Heideman, D. Jones, W. R. Crom, and C. B. Pratt. 1994. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol. 12: 19461954. 40. Strazielle, N., and J. F. Ghersi-Egea. 1999. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J. Neurosci. 19: 62756289. 41. Sun, H., D. W. Miller, and W. F. Elmquist. 2001. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18: 15421549. 42. Tanaka, Y., Y. Abe, A. Tsugu, Y. Takamiya, A. Akatsuka, T. Tsuruo, H. Yamazaki, Y. Ueyama, O. Sato, and N. Tamaoki. 1994. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch. 425: 133138. 43. Tatsuta, T., M. Naito, T. Oh-hara, I. Sugawara, and T. Tsuruo. 1992. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267: 2038320391. 44. van Aubel, R. A., P. H. Smeets, J. G. Peters, R. J. Bindels, and F. G. Russel. 2002. The MRP4 ABCC4 gene encodes a novel apical organic anion trans and tranylcypromine.

Topotecan in ovarian cancer

Frequency of 90-day survival P 0.00001 ; . No adverse sequelae were apparent in the animals treated with DB67. Animals that died all had evidence of intracranial tumor on examination. DISCUSSION The first clinically applied topo inhibitor, camptothecin, was extracted from the wood, bark, and fruit of an Oriental tree, Camptotheca acuminata 38 ; , which had long been used in Chinese medicine for the treatment of a variety of ailments, including neoplasms. Although studies by the National Cancer Institute established the antitumor activity of this agent in preclinical models 39 ; , clinical testing of this agent demonstrated only modest efficacy with unacceptable toxicity 6, 11 ; . These initial clinical results temporarily quelled enthusiasm for further examination of this compound or its derivatives. However, with the subsequent demonstration that this agent was actually a site-specific inhibitor of the enzyme topo I, which plays an essential role in DNA replication and transcription 10, 11 ; , interest was renewed in developing more effective, better tolerated camptothecin derivatives. Factors that contributed to poor efficacy and unacceptable toxicity of camptothecin were identified, and efforts were made to modify the parent compound to a more suitable derivative. The principal problems included poor solubility and limited bioavailability secondary to albumin binding and rapid acyl cleavage at physiological pH of the -hydroxy lactone moiety to a biologically inactive carboxylate form that was nonetheless potentially toxic to normal cells 6, 10, 11, ; . A number of derivatives, such as 9-aminocamptothecin 41 ; , irinotecan CPT-11; Refs. 12, 42 44 ; , topotecan 13, 45 ; , and 7-ethyl-10, 11-methylenedioxycamptothecin 46 ; were formulated, which overcame some but not all of the above limitations with varying degrees of success. The synthesis schema that was pursued for the compounds reported here was directed at producing a family of synthetic camptothecin analogues that exhibited improved in vivo stability while preserving or enhancing topo I inhibitory activity. The cascade radical annulation reaction provided a totally synthetic approach to the formulation of such compounds that permitted significant flexibility in drug design to and topotecan. The authors have reviewed the activity of topotecan in small cell lung cancer, and have given us some ideas as to the direction in which the incorporation of topotecan into this disease is heading and treprostinil.

Is a result of patients not taking their medication correctly.6 Patients are advised to stay upright for at least 30 minutes after taking alendronate and at least 60 minutes after taking ibandronate. These medications are contraindicated in patients who cannot follow the administration instructions and in those with coexisting esophageal disorders that prevent normal esophageal emptying.4, 7 In those patients who find it difficult to follow the complex dosing instructions, especially the elderly, the once-weekly and now once-monthly bisphosphonates would decrease this burden. Nonsteroidal anti-inflammatory drugs NSAIDs ; are well known for causing gastric and duodenal ulcers and may also cause esophageal injury.3 One of the mechanisms by which this occurs is the fast dissolution rates of these agents which can expose the esophageal mucosa to the injurious medications before the esophagus can clear itself.1 All of the NSAIDs have the potential to cause esophageal damage, but the most common ones are naproxen, ibuprofen, aspirin, and indomethacin.8 It is important to notice that 3 out of the 4 of these NSAIDs are OTC medications, therefore it is imperative to counsel patients about the potential for these GI side effects and esophageal injury before they begin to take the medication. One specific population who seems to be more prone to esophageal injury with NSAIDs is the elderly, possibly due to the fact that many have arthritis and fractures and use NSAIDs more regularly.3 To reduce the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration.9 Esophageal injuries that are caused by NSAIDs usually heal shortly after the cessation of the offending agent.1 A comparison of bisphosphonates and NSAIDs can be found in Table 1.1 There are several preventive measures to minimize the risk of drug-induced esophageal injury. A considerable amount of liquid taken after the drug is imperative in the minimization of esophageal damage. It is recommended that at least 100 mL of liquid be used as a post-dose chaser and that a lubricating sip of water prior to administration may also be helpful.1 For the bisphosphonates, six to eight ounces of plain water should be taken along with the medication.4, 7 For medications taken at bedtime, patients should take the dose five to ten minutes prior to lying down to improve esophageal clearance.1 It is important for pharmacists and other health care professionals to counsel patients on a regular basis about the safe administration of their medications to minimize esophageal injury, especially for the bisphosphonates. Taking those medications appropriately i.e. standing sitting for 30-60 minutes after administration and drinking six to eight ounces of water with the medication ; is the best way to minimize bisphosphonate-induced esophageal injury. Patients should also be encouraged to report any swallowing pain or difficulty to their physician or pharmacist. If patients are having problems taking their medications correctly, liquid formulations may be preferable since they reach the stomach faster; however, in some patients with dysphagias even liquids could reflux and cause injury. Recommendations for the prevention of esophageal damage are listed in Table 3.1 For management and treatment of esophageal injury, several factors must be considered. The type and severity of esophageal damage and the overall condition of the patient will dictate the best treatment. In the majority of esophageal injury cases, discontinuation of the causative agent will resolve the damage in days to weeks.2 Several different classes of medications have been used in the treatment of esophageal injury, including viscous lidocaine for pain control, and proton-pump inhibitors PPI's ; , H2-receptor blockers, antacids, sucralfate, and prednisone to speed healing.1, 8 For the management and treatment of NSAID-induced esophageal injury, PPI's and H2-receptor blockers are commonly given in conjunction with an NSAID. In severe cases of bisphosphonate-induced esophageal injury, discontinuation of the agent is crucial, along with the addition of acid-suppressive therapy or sucralfate, and or local or systemic analgesia.8 In summary, esophageal injury can in fact be drug-induced. Healthcare professionals, especially doctors, pharmacists and nurses, can play an important role in helping to prevent, identify, minimize, and treat esophageal injury by simply recognizing the risk factors and knowing the medications that are commonly associated with esophageal injury. By educating patients and caregivers about the safe administration of their medications and monitoring their.

Navelbine topotecan ovarian cancer

Regimens 27 ; . One patient who received fludarabine, carboplatin, topotecan regimen with a 25% dose reduction as consolidation therapy died of bone marrow aplasia 81 days after receiving treatment, raising a concern that hematologic toxicity of the regimen may be cumulative. The maximum tolerated dose of topotecan and carboplatin in the fludarabine, carboplatin, topotecan regimen for acute leukemia appears to be approximately twice that observed for solid tumors 10 ; . At the dose range studied, we found significant interpatient variation of steady-state lactone and total topotecan plasma concentrations within dose levels and did not observe a significant relationship between dose and plasma concentration of topotecan. The consistent ratio of steady-state total topotecan to plasma lactone concentration suggests that sample processing and analysis were accurate. However, the number of patients available for analysis may not have been sufficient to determine any significant correlation between steady-state plasma topotecan concentration and early treatment bone marrow or clinical response. On the other hand, it is of interest that all of the clinical responses were observed at dose level 3 or greater, suggesting that topotecan added significantly to the antileukemic activity of the regimen. In our study, increased plasma concentrations of topotecan correlated significantly with days to neutrophil recovery. Other investigators have observed up to a 10-fold interpatient variability between dose administered and topotecan pharmacokinetics 28 30 ; . Moreover, topotecan plasma concentrations rather than dose administered have been shown to correlate with the development of hematologic and gastrointestinal toxicities 28, 3134 ; , suggesting that future studies may warrant consideration of dosing of topotecan based on pharmacokinetics 35 ; . Enhanced cytotoxicity between carboplatin and topotecan in the fludarabine, carboplatin, topotecan regimen may be related to the potential for DNA damaging agents such as carboplatin to increase topoisomerase I activity. However, in the current study we did not observe a correlation between upregulation of topoisomerase I activity and tumor response among the 13 paired patient samples analyzed. Kanzawa et al. 36 ; found that the topoisomerase I inhibitory effect of irinote and triac. EXAMPLE 4 B. is fifty year-old non-diabetic woman who carried 201-1 2 lbs on a 5'1" frame. In just about seven months she has come down to 142-1 2 lbs. Although she is not diabetic and has no family history of diabetes, she does have a family history of obesity. Her hemoglobin A1C was 5.2, which corresponds to an average blood and toradol.

Topotecan topoisomerase

American college of nurse midwives cnm, cheap viagra from india, remeron discontinuation, arteriosclerosis atherosclerosis treatment and ondansetron migraine. Virology lab, biofilm stages, calcium 6 plus and cholecystitis race or torture of females.

Topotecan weekly ovarian

Topotrcan, topo6ecan, topot3can, topotecwn, topoetcan, topptecan, topotecab, toptoecan, t0potecan, topot4can, gopotecan, opotecan, topoteca, topoteacn, topotcean, tooptecan, topotecxn, 6opotecan, topo5ecan, topotecsn.

Topotecan injection

Topotecan patient assistance, topotecan and avastin for ovarian cancer, topotecan msds, discount generic topotecan online and topotecan in ovarian cancer. Navelbine topotecan ovarian cancer, topotecan topoisomerase, topotecan weekly ovarian and topotecan injection or topotecan for men.

Free Web Hosting